Skip to main content
. Author manuscript; available in PMC: 2013 Sep 10.
Published in final edited form as: JAMA Ophthalmol. 2013 Apr;131(4):422–429. doi: 10.1001/jamaophthalmol.2013.1497

Table 5.

Multiple Linear Regression Predicting 3-Month Best Spectacle-Corrected Visual Acuity

Covariate Coefficient, logMAR SE 95% CI P Value
Model with enrollment BSCVA and treatment arm
 Enrollment BSCVA 0.72 0.08 0.56 to 0.89 <.001
 Natamycin vs voriconazole −0.18 0.06 −0.30 to −0.05 .006
Model with interaction for Fusarium species
 Enrollment BSCVA 0.71 0.08 0.55 to 0.87 <.001
 Natamycin vs voriconazole
  Fusarium species −0.41 0.11 −0.61 to −0.20 <.001
  Non-Fusarium species −0.02 0.08 −0.17 to 0.13 .81

Abbreviation: BSCVA, best spectacle-corrected visual acuity.